Sponsor pipeline

Haitao Zhao, MD clinical trial pipeline

4 active trials 4 recruiting 2 disease areas 1 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-11

What changed in the last 30 days

1 trial changed in the last 30 days: 0 stopped, 0 with notable changes, 1 with a minor change only.

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

First posted	Trial	Phase	Status
2026-10-02	NCT07854600 A Phase II Study of Ivonescimab in Combination With GEMOX as Neoadjuvant and Conversion…	Phase 2	Recruiting
2026-09-30	NCT07850791 A Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary…	Phase 2	Recruiting

Phase 2

Not charted: 1 active trial with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

NCT ID	Title	Condition	Status	Updated
Phase 2
NCT07850791	A Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary…	Biliary Tract Cancer (BTC)	Recruiting	2026-10-05
NCT07854600	A Phase II Study of Ivonescimab in Combination With GEMOX as Neoadjuvant and Conversion…	Biliary Tract Cancer (BTC)	Recruiting	2026-10-02
NCT07786766	Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2…	Biliary Tract Cancer (BTC)	Recruiting	2026-08-26
Not specified
NCT07142213	Effect and Mechanism of ALPPS Operation on Liver Regeneration	Hepato Cellular Carcinoma (HCC)	Recruiting	2025-08-26

Get alerts when Haitao Zhao, MD's trials change

Status changes, date slips, and new filings: detected daily, delivered to your inbox.